The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension

BACKGROUND AND AIMS: Angiogenesis is critically involved in the development of liver fibrosis, portal hypertension (PHT) and hepatocellular carcinoma (HCC). Regorafenib is a novel second-line therapy for HCC, but might also be beneficial in fibrosis and PHT even in absence of HCC. This study investi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Uschner, Frank Erhard, Schueller, Florian, Nikolova, Ivelina, Klein, Sabine, Schierwagen, Robert, Magdaleno, Fernando, Gröschl, Stefanie, Loosen, Sven, Ritz, Thomas, Roderburg, Christoph, Vucur, Michael, Kristiansen, Glen, Lammers, Twan, Luedde, Tom, Trebicka, Jonel
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2018
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6281422/
https://ncbi.nlm.nih.gov/pubmed/30546838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26333
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi